Publications by authors named "Adriana Martinez Turtos"

Despite recent treatment advances, non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related deaths worldwide, and therefore it necessitates the exploration of new therapy options. One commonly shared feature of malignant cells is their ability to hijack metabolic pathways to confer survival or proliferation. In this study, we highlight the importance of the polyol pathway (PP) in NSCLC metabolism.

View Article and Find Full Text PDF

Cancer metabolic reprogramming has been recognized as one of the cancer hallmarks that promote cell proliferation, survival, as well as therapeutic resistance. Up-to-date regulation of metabolism in T-cell lymphoma is poorly understood. In particular, for human angioimmunoblastic T-cell lymphoma (AITL) the metabolic profile is not known.

View Article and Find Full Text PDF
Article Synopsis
  • EMT is a process that helps cancer cells spread and become resistant to treatment, making it a big challenge in fighting cancer.
  • Researchers found that short-chain fatty acids like propionate can help stop this process in lung cancer cells, making them less aggressive.
  • Propionate not only helps lung cancer cells stick together but also reduces their ability to spread in mice, showing promise for new treatments in the future.
View Article and Find Full Text PDF

IRE1α is one of the three ER transmembrane transducers of the Unfolded Protein Response (UPR) activated under endoplasmic reticulum (ER) stress. IRE1α activation has a dual role in cancer as it may be either pro- or anti-tumoral depending on the studied models. Here, we describe the discovery that exogenous expression of IRE1α, resulting in IRE1α auto-activation, did not affect cancer cell proliferation but resulted in a tumor-suppressive phenotype in syngeneic immunocompetent mice.

View Article and Find Full Text PDF
Article Synopsis
  • Using a special enzyme called l-asparaginase (ASNase) to lower asparagine is important for treating leukemia and other cancers.
  • Researchers found that the amount of an enzyme called asparagine synthetase (ASNS), which makes asparagine, doesn't always predict how well cancer cells will respond to ASNase treatment.
  • They also discovered that ASNase works better because it can break down another substance, and this should be taken into account when treating most cancer cells, not just the ones missing ASNS.
View Article and Find Full Text PDF

Chimeric antigen receptor (CAR) T and CAR NK cell therapies opened new avenues for cancer treatment. Although original successes of CAR T and CAR NK cells for the treatment of hematological malignancies were extraordinary, several obstacles have since been revealed, in particular their use for the treatment of solid cancers. The tumor microenvironment (TME) is competing for nutrients with T and NK cells and their CAR-expressing counterparts, paralyzing their metabolic effective and active states.

View Article and Find Full Text PDF

Programmable nucleases have enabled rapid and accessible genome engineering in eukaryotic cells and living organisms. However, their delivery into human blood cells can be challenging. Here, we have utilized "nanoblades," a new technology that delivers a genomic cleaving agent into cells.

View Article and Find Full Text PDF

Background: There is growing interest in the analysis of tumor metabolism to identify cancer-specific metabolic vulnerabilities and therapeutic targets. Finding of such candidate metabolic pathways mainly relies on the highly sensitive identification and quantitation of numerous metabolites and metabolic fluxes using metabolomics and isotope tracing analyses. However, nutritional requirements and metabolic routes used by cancer cells cultivated in vitro do not always reflect the metabolic demands of malignant cells within the tumor milieu.

View Article and Find Full Text PDF